{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T12:39:39Z","timestamp":1788698379213,"version":"build-2803163510"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T00:00:00Z","timestamp":1742688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T00:00:00Z","timestamp":1742688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1038\/s41409-025-02558-6","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T11:48:31Z","timestamp":1742730511000},"page":"743-745","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of daratumumab on the development of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma"],"prefix":"10.1038","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7529-5585","authenticated-orcid":false,"given":"Daisuke","family":"Minakata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4523-2994","authenticated-orcid":false,"given":"Shin-ichiro","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seina","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2113-7631","authenticated-orcid":false,"given":"Ryutaro","family":"Tominaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daizo","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuto","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuka","family":"Furuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Murahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotomo","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Hyodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichiro","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Toda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyomi","family":"Mashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Umino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masuzu","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ashizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5333-8414","authenticated-orcid":false,"given":"Chihiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2876-4224","authenticated-orcid":false,"given":"Kazuya","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Ohmine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyoshi","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4866-9307","authenticated-orcid":false,"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,23]]},"reference":[{"key":"2558_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","volume":"394","author":"P Moreau","year":"2019","unstructured":"Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394:29\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(19)31240-1.","journal-title":"Lancet"},{"key":"2558_CR2","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136:936\u201345. https:\/\/doi.org\/10.1182\/blood.2020005288.","journal-title":"Blood"},{"key":"2558_CR3","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024;390:301\u201313. https:\/\/doi.org\/10.1056\/NEJMoa2312054.","journal-title":"N Engl J Med"},{"key":"2558_CR4","first-page":"175","volume":"16","author":"CK Lee","year":"1995","unstructured":"Lee CK, Gingrich RD, Hohl RJ, Ajram KA. Engraftment syndrome in autologous bone marrow and peripheral stem cell transplantation. Bone Marrow Transpl. 1995;16:175\u201382.","journal-title":"Bone Marrow Transpl"},{"key":"2558_CR5","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1016\/j.bbmt.2015.08.030","volume":"21","author":"RF Cornell","year":"2015","unstructured":"Cornell RF, Hari P, Drobyski WR. Engraftment syndrome after autologous stem cell transplantation: an update unifying the definition and management approach. Biol Blood Marrow Transpl. 2015;21:2061\u20138. https:\/\/doi.org\/10.1016\/j.bbmt.2015.08.030.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2558_CR6","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/sj.bmt.1703015","volume":"27","author":"TR Spitzer","year":"2001","unstructured":"Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transpl. 2001;27:893\u20138. https:\/\/doi.org\/10.1038\/sj.bmt.1703015.","journal-title":"Bone Marrow Transpl"},{"key":"2558_CR7","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/sj.bmt.1703855","volume":"31","author":"A Maiolino","year":"2003","unstructured":"Maiolino A, Biasoli I, Lima J, Portugal AC, Pulcheri W, Nucci M. Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria. Bone Marrow Transpl. 2003;31:393\u20137. https:\/\/doi.org\/10.1038\/sj.bmt.1703855.","journal-title":"Bone Marrow Transpl"},{"key":"2558_CR8","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.bbmt.2013.06.017","volume":"19","author":"RF Cornell","year":"2013","unstructured":"Cornell RF, Hari P, Zhang MJ, Zhong X, Thompson J, Fenske TS, et al. Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma. Biol Blood Marrow Transpl. 2013;19:1368\u201373. https:\/\/doi.org\/10.1016\/j.bbmt.2013.06.017.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2558_CR9","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s12185-019-02615-z","volume":"109","author":"H Takamatsu","year":"2019","unstructured":"Takamatsu H, Yoroidaka T, Fujisawa M, Kobori K, Hanawa M, Yamashita T, et al. Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry. Int J Hematol. 2019;109:377\u201381. https:\/\/doi.org\/10.1007\/s12185-019-02615-z.","journal-title":"Int J Hematol"},{"key":"2558_CR10","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 2013;48:452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transpl"},{"key":"2558_CR11","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","volume":"128","author":"J Krejcik","year":"2016","unstructured":"Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128:384\u201394. https:\/\/doi.org\/10.1182\/blood-2015-12-687749.","journal-title":"Blood"},{"key":"2558_CR12","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-16-3192","volume":"23","author":"X Feng","year":"2017","unstructured":"Feng X, Zhang L, Acharya C, An G, Wen K, Qiu L, et al. Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma. Clin Cancer Res. 2017;23:4290\u2013300. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-3192.","journal-title":"Clin Cancer Res"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02558-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02558-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02558-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T14:28:15Z","timestamp":1746714495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02558-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,23]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2558"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02558-6","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,23]]},"assertion":[{"value":"9 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.M. has received speaking fees from Janssen. M.A. has received speaking fees from Novartis. M.U. has received speaking fees from Janssen, Ono Pharma, Sanofi, Takeda, and BMS. S.-i.F. has received a scholarship from Daiichi Sankyo and honoraria from BMS, CSL Behring, Janssen, Nippon Kayaku, Novartis, Pfizer, Sanofi, and Takeda. K.O. serves as an advisor for Ono and has received speaking fees from Novartis, Takeda, and Ono. Y.K. has received research grants from Sanofi, Ono, Takeda, and Daiichi Sankyo, and payment or honoraria for lectures from BMS, Janssen, Sanofi, Novartis, Pfizer, Ono, Takeda, and Daiichi Sankyo. The other authors have no conflicts of interest to report.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"We confirm that all methods were performed in accordance with the relevant guidelines and regulations. This retrospective analysis was approved by the institutional review boards Jichi Medical University Hospital Bioethics Committee for Clinical Research [23-125, 31\/Jan\/2024]. Regarding the patient consent statement, this study was a retrospective analysis and did not require patient consent. An opt-out procedure was used, and participants were not included in the study if they explicitly decided to exclude. We have not released any personally identifiable images from human research participants in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}